Serial No.: To be assigned

IN RE: Application of: Kathleen SMITH, et al.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit: To be assigned

Filing Date:	Concurrently Herewith Examiner: To be assigned							
For: GENERATION OF RECOMBINANT GENES IN SACCHAROMYCES CEREVISIAE								
P.O. Box 14	ner for Patents 450 , VA 22313-1450							
INFORMATION DISCLOSURE STATEMENT								
	request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner $\frac{1}{2}$ by made of record in accordance with the provisions of 37 CFR 1.97							
[] Co [X] A e <u>PC</u> Re	pies of the following references are enclosed. pies of the references were submitted in parent application Serial No							
A. [X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).							
[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).							
В. []	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.							
[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.							
[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information							

Disclosure Statement under § 1.97(c) (\$180.00).

JAP20 Rec'd PCT/PTO 28 JUL 2006

C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [] Applicant hereby certifies that no item of information contained in this Information Disclosure
 Statement was cited in a communication from a foreign patent office in a counterpart foreign
 application, and, to my knowledge after making reasonable inquiry, no item of information
 contained in this Information Disclosure Statement was known to any individual designated in §
 1.56(c) more than three months prior to the filing of this statement; and
- The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [X] A duplicate copy of this paper is attached.

Respectfully Submitted,

Frank P. Grassler, Attorney of Record

Registration No. 31,164

Date: July 28, 2006 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-2482 Facsimile: (919) 483-5730

JAP20 Ras'c Futing 0 28 JUL 2006

C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign paper and office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement, and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [X] A duplicate copy of this paper is attached.

Respectfully Submitted,

Frank P. Grassler, Attorney of Record Registration No. 31,164

Date: July 28, 2006 GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398 Telephone: (919) 483-2482

Facsimile: (919) 483-5730

¿AP20 Rec'd PCT/PTO 28 JUL 2006

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					ATTORNEY DOCKET NO. 3 SERIADIO / O D 1 PLP573 To be assigned				
					APPLICANT: Katl	ileen SMITI			
					FILING DATE:		GROUP		
					Concurrently Herew	rith	To be assigned	<u> </u>	
			U.S. P	ATENT D	OCUMENTS				
Examiner Initials		Patent Number			Name	Class	Subclass	Filing Date If Appropriate	
	-		1	 			1		
	\vdash					-			
	-			-		_			
	-			+		+			
			c	ontinue on p	age		1	·	
					DOCUMENTS				
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No	
	_						-		
	-		-			+	-		
	-					1			
					•				
	L			L					
		OTHER DOCUM		ontinue on p		Page Numb	er Etc.)		
/RAZ/	1.	OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Palluh, J.L., "Mudational Analysis of the Gene for Schizosaccaronyces Pombe RNASE MPR RNA, MRPL, Using Plasmid Shuffle by Counterselection on Canavarnine," YEAST, Chichester, Sussex, GB, vol. 12, no. 14 November 1996, pp. 1393-1405.							
/RAZ/	2.	Abecassis, V., et al., "High efficiency family shuffling based on multi-step PCR and in vivo DNA recombination in yeast statistical and functional analysis of a combinatorial library between human cytochrome P450 A1A and 1A2." NUCLEAIC ACIDE RESEARCH, vol. 28, no. 20, October 15, 2000, no. E88-E88-E8							
	T-				20,110.20,00000	.о, 2000, рр.	200 200.		
	_								
	\vdash	-							
	\vdash								
	├								
					_				
				Continue on	page				
EXAMINER /Robert Zeman/						DATE CONSIDERED 03/10/2010			
					s in conformance with	MPEP § 609	; Draw line thr		
if not in conf	formano	e and not considere	d. Include copy	of this form	with next communica	tion to the ap	plicant.		